Solicitation for BAA-DAIT-75N93021R00008 entitled, "Advancing Vaccine Adjuvant Research for Tuberculosis (TB)"
Contract Opportunity Type: Solicitation
The goal of this program is to further the development of TB vaccines through sideby-side comparisons of adjuvants in combination with TB immunogens, and to establish immunological profiles of adjuvants that work through different mechanisms, facilitating the identification of the most promising adjuvant:Mtb immunogen candidates for clinical development and potential immune correlates of protection. The range of adjuvants to be evaluated may include novel classes of adjuvants being developed for other infections and immune-oncology therapeutics, as well as adjuvants already being developed for TB vaccines. It is anticipated that one cost reimbursement, completion type contract will be awarded for a five -year period of performance beginning on or about 7/22/22.
NIAID anticipates that the average annual total cost (direct and indirect costs combined) is $4 million per contract. However, it is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed five  years. Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about April, 28, 2021, and may be accessed through here. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.
Published: Apr 28, 2021 12:41 pm EDT
Offers Due: Aug 10, 2021 03:00 pm EDT